FIG. 5.
LPL is a novel HBV binding protein. (A) Schematic view of the three-dimensional model of human LPL (25). The PreS-binding motif is exposed in a surface loop, residues 382 to 396 between the stacked sheets in the C-terminal domain. (B) GST-pC (lanes 1 and 2), GST-LPLc (lanes 3 and 4), and GST-LPLcm (W393W394→AA) (lanes 5 and 6) were assessed for binding to PreS11-65 (lanes 1, 3, and 5) and PreS11-20 (lanes 2, 4, and 6). (C) Virus capture assay with FLAG-tagged LPLc. HBV particles from serum samples were applied to FLAG-LPLc-immobilized streptavidin-coated wells. OD450, optical density at 450 nm. Error bars indicate standard deviations. (D) Virus capture by recombinant LPL produced in COS cells. Upper panel, recombinant LPL protein with a C-terminal FLAG tag (lane 1) and the corresponding mutant (lane 2) from lysates of transfected COS cells were verified by Western blotting with anti-FLAG MAb. Lane 3, COS cell lysate without transfection. Lower panel, LPL proteins from cell lysates were applied to anti-FLAG-coated wells and used to capture virus particles.